Premature Ovarian Insufficiency: cell-therapy evidence by therapy class
Across every stem-cell intervention, ClinicalTrials.gov holds 36 registered records for Premature Ovarian Insufficiency — 3 recruiting, 3 at Phase 3 or 4, in 16 countries. Snapshot 2026-08-29.
The condition, and why cells are proposed
Primary ovarian insufficiency is loss of ovarian function before forty, from genetic, autoimmune or iatrogenic causes. Cell and platelet-based 'ovarian rejuvenation' aims to restore folliculogenesis. Occasional spontaneous ovulation occurs in this condition — including spontaneous pregnancies — which is the fact most often exploited by uncontrolled case reports.
Therapy classes side by side
Counts come from separate registry queries per class; a study testing two interventions can appear in more than one row, so rows do not sum to the all-interventions total.
Geography of the research
China accounts for about 43% of country mentions among sampled studies; 16 countries host at least one site.
| Country | Studies with a site there |
|---|---|
| China | 13 |
| Egypt | 5 |
| United States | 4 |
| Spain | 2 |
| Ukraine | 1 |
| Malta | 1 |
| North Macedonia | 1 |
| Serbia | 1 |
The largest registered studies
Sorted by planned enrolment — size is not quality, but a 300-participant trial can answer questions a 12-participant series cannot.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT03033277 — Human Umbilical Cord Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Women With Primary Ovarian Insufficiency (POI) | Phase 1, Phase 2 | Unknown | 320 | Chinese Academy of Sciences | 2016-02 |
| NCT05667428 — A Multicenter Open-label Clinical Study on the Prevention of Premature Ovarian Failure After HSCT | n/a | Unknown | 200 | First Affiliated Hospital Xi'an Jiaotong University | 2023-03-01 |
| NCT02372474 — "It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure | Phase 1, Phase 2 | Completed | 112 | Al-Azhar University | 2012-03 |
| NCT04009473 — Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation | Phase 1, Phase 2 | Unknown | 100 | Forever Young d.o.o. | 2019-06-01 |
| NCT04675970 — Long Term Follow up Patients With Premature Ovarian Failure ex Vivo Gene Therapy | n/a | Completed | 86 | Ukraine Association of Biobank | 2020-09-01 |
| NCT03021915 — Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure | n/a | Suspended | 81 | OvaScience, Inc. | 2016-10 |
Most recently registered
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT05494723 — Safety and Efficacy of YB-1113 in Treatment of POI | n/a | Not Yet Recruiting | n/a | Bright Cell, Inc. | 2026-12-09 |
| NCT07775391 — Phase Ⅰ/Ⅱa Trial Evaluating Intravenous hUC-MSCs Injection for Safety, Tolerability and Efficacy in Patients With POI | n/a | Recruiting | n/a | Shenzhen Wingor Biotechnology Co., Ltd. | 2026-08-03 |
| NCT07511660 — Intra Ovarian Muse Cell Injection for Perimenopause Symptom Relief and Ovarian Function Restoration (MUSE-OVARY) | n/a | Enrolling By Invitation | n/a | Healing Hope International | 2026-06-01 |
| NCT07551895 — Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Primary Ovarian Insufficiency | n/a | Not Yet Recruiting | n/a | Shenzhen Huishan Biotechnology Co., Ltd. | 2026-04-15 |
| NCT07510139 — A Clinical Study of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Premature Ovarian Insufficiency | n/a | Active Not Recruiting | n/a | International Peace Maternity and Child Health Hospital | 2026-03-20 |
Reading this honestly
Registration counts measure activity, not effect. A study appears here the moment it is registered — before any participant is enrolled, and regardless of whether results are ever posted. For Premature Ovarian Insufficiency specifically, the practical question is which registered study — if any — matches the product a provider is offering, and what its outcome measures actually are.
Frequently asked
How many stem-cell trials exist for Premature Ovarian Insufficiency?
36 registered records mention a stem-cell intervention for this condition (2026-08-29 snapshot), of which 3 were recruiting.
Which therapy class is furthest along for Premature Ovarian Insufficiency?
Ranked by Phase 3/4 records: PRP (2), HSCT (1), MSC (0), exosomes (0).
Does a recruiting trial mean I can be treated?
No. Trials have eligibility criteria, and joining one is not the same as buying a treatment. Paying a clinic for an unproven intervention outside a registered study gives you neither the protections nor the data collection of a trial.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Premature Ovarian Insufficiency: cell-therapy evidence and registered trials
- How much does stem cell therapy for Premature Ovarian Insufficiency cost? (2026)
- Premature Ovarian Insufficiency stem cell therapy — your questions answered (2026)
- MSC vs PRP for Premature Ovarian Insufficiency: what the registries show
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.